Jaguar Health Inc Stock Price, News & Analysis

Jaguar Health, Inc. (NASDAQ:JAGX) announced the grant of nonstatutory stock options and restricted stock units (RSUs) to two new employees, effective October 25, 2021. New Employee 1 received options for 2,666 shares and 1,333 RSUs, while New Employee 2 received options for 1,583 shares and 791 RSUs, all with an exercise price of $2.02 per share. The options vest over three years, and the RSUs vest equally over the same period. These grants were approved by the Board's Compensation Committee as an incentive for the new hires.

Jaguar Health announced that the merger between its Italian subsidiary, Napo EU S.p.A., and Dragon SPAC S.p.A. is set to be completed within a week. The merger has received clearance from the Italian government under the 'Golden Powers' process. The new entity will hold an exclusive license for the crofelemer pipeline in Europe, with significant up-front fees and royalties due to Jaguar. Napo EU will primarily focus on obtaining conditional marketing authorization for crofelemer, aimed at treating short bowel syndrome.

Jaguar Health (NASDAQ:JAGX) announced updates on its crofelemer drug candidates and the merger with Dragon SPAC and Napo EU. The required regulatory notification for the merger has been submitted to the Italian government. The HALT-D study results on crofelemer for diarrhea prevention in breast cancer patients will be presented at the San Antonio Breast Cancer Symposium in December 2021. Additionally, discussions with the FDA regarding NP-300 for acute diarrhea relief were positive, and Canalevia for treating dogs' chemotherapy-induced diarrhea is set to launch in December 2021.

Jaguar Health, Inc. (JAGX) announces that Founder and CEO Lisa Conte will receive an Impact Award from Pure Earth for her dedication to supporting Indigenous communities and sustainable medicine. The award ceremony is set for October 4, 2021, in New York City. Under Conte's leadership, Jaguar developed crofelemer, the first FDA-approved plant-based oral medicine from the Croton lechleri tree, with over 800,000 trees planted. Pure Earth, recognized for its global pollution reduction efforts, praises Conte as a visionary in pharmaceuticals.

Jaguar Health (NASDAQ:JAGX) announced an R&D Showcase webinar on September 29, 2021, focusing on cancer therapy-related diarrhea (CTD). Hosted by Ladenburg Thalmann, the webinar will feature insights from leading oncologists and Jaguar's CEO Lisa Conte. The event aims to highlight the importance of supportive care for cancer patients struggling with diarrhea due to therapy. It is open to investors and financial analysts. Jaguar's subsidiaries focus on plant-based gastrointestinal medicines.

Jaguar Health announced on September 21, 2021, that it received confirmation from the FDA's Center for Veterinary Medicine that the Target Animal Safety section of its application for the conditional approval of Canalevia for chemotherapy-induced diarrhea (CID) in dogs is complete. Canalevia, an oral plant-based drug, aims to help dogs undergoing chemotherapy, addressing a significant issue as approximately 40% of treated dogs experience diarrhea that may affect treatment. Launch is expected in December 2021.

Jaguar Health (NASDAQ:JAGX) announced an investor webcast scheduled for September 20, 2021, at 8:30 AM Eastern Time. The company is also launching an educational awareness contest in honor of Indigenous Peoples' Day on October 11, 2021. This fifth contest aims to honor Indigenous healers and will award a winner a book on ethnobotany. Participants must submit answers to multiple-choice questions by 9:00 AM on the contest date. Jaguar Health focuses on developing plant-based pharmaceuticals for gastrointestinal issues.

Jaguar Health (NASDAQ:JAGX) announced that the European Medicines Agency (EMA) has accepted the orphan drug designation application for crofelemer for treating short bowel syndrome with intestinal failure (SBS-IF). This acceptance initiates a formal review process by the EMA's Committee for Orphan Medicinal Products. The company aims to secure conditional marketing authorization in Europe, focusing on this critical orphan disease. Crofelemer, previously designated as an orphan drug by the FDA for SBS in the U.S., has significant market potential, especially given that approximately 10,000 to 20,000 patients may be affected in both the U.S. and Europe.

Jaguar Health (NASDAQ:JAGX) has successfully completed a $776,200 private placement of approximately 309,242 shares of Common Stock. This offering, led by impact investor Josh Mailman and including Jaguar's CEO and CFO, was priced at a premium to market. The company's subsidiary, Napo EU, aims to expand access to its drug crofelemer in Europe, specifically targeting short bowel syndrome. A merger with Dragon SPAC is pending regulatory approval, expected by early October 2021. Ismaila Sougoufara has been promoted to Senior Director, Corporate Controller.